aspirin has been researched along with Neoplasm Metastasis in 97 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We conducted a prospective randomized trial of alpha-interferon given with or without indomethacin to patients with malignant melanoma to determine what effect, if any, indomethacin might have on the toxic, immunomodulatory, and therapeutic properties of interferon in this disease." | 9.06 | Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma. ( Clark, JW; Crum, E; Hawkins, MJ; Jones, MJ; Longo, DL; McKnight, JE; Miller, RL; Smith, JW; Steis, RG; Urba, WJ, 1989) |
| "Clinical evidence recently suggests that the regular use of aspirin is associated with a lower risk of breast cancer metastasis, but mechanisms remain unclear." | 8.12 | Aspirin suppresses breast cancer metastasis to lung by targeting anoikis resistance. ( Chen, W; Dong, Z; Li, H; Xu, R; Yan, Y; Zhang, H; Zheng, X, 2022) |
| " Aspirin use post-diagnosis may modify components of the PI3K pathway, including AKT and mTOR, and has been associated with lower risk of breast cancer recurrence and mortality." | 7.96 | Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer. ( Armstrong, K; Bardia, A; Chan, AT; He, W; Iafrate, AJ; Kumar, NP; McCarthy, AM; Moy, B; Regan, S; Welch, M, 2020) |
| "Metformin can induce breast cancer (BC) cell apoptosis and reduce BC local and metastatic growth in preclinical models." | 7.83 | Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. ( Albini, A; Bertolini, F; Calleri, A; Dallaglio, K; Gregato, G; Labanca, V; Mancuso, P; Noonan, DM; Orecchioni, S; Reggiani, F; Rossi, T; Talarico, G, 2016) |
| "Sorafenib is considered to be the first-line therapy for advanced hepatocellular carcinoma (HCC)." | 7.81 | Down-regulation of SDF1-α expression in tumor microenvironment is associated with aspirin-mediated suppression of the pro-metastasis effect of sorafenib in hepatocellular carcinoma. ( Chen, J; Jia, H; Lu, L; Lu, M; Pei, Y; Qin, L; Zhu, W, 2015) |
| "MTT assay, colony formation assay, and apoptosis assay were employed to analyze the effects of aspirin on the osteosarcoma cell viability in vitro." | 7.81 | Aspirin Suppresses the Growth and Metastasis of Osteosarcoma through the NF-κB Pathway. ( Duan, T; Hu, K; Kang, T; Liao, D; Lv, X; Wang, G; Wang, X; Zhang, RH; Zhong, L, 2015) |
| "We previously demonstrated the pro-metastasis effect of sorafenib in hepatocellular carcinoma (HCC), which is mediated by down-regulation of tumor suppressor HTATIP2." | 7.79 | Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma. ( Ao, JY; Chai, ZT; Kong, LQ; Li, JQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Zhang, KZ; Zhang, QB; Zhang, W; Zhang, YY; Zhu, XD, 2013) |
| " We therefore assessed the effect of Indomethacin and aspirin on some parameters of calcium metabolism in patients with breast cancer." | 7.65 | Failure of indomethacin to reduce hypercalcemia in patients with breast cancer. ( Bondy, PK; Coombes, RC; Neville, AM; Powles, TJ, 1976) |
| "Aspirin could reduce the risk of cancer metastasis." | 6.87 | The effect of aspirin on circulating tumor cells in metastatic colorectal and breast cancer patients: a phase II trial study. ( Chen, Y; Hu, X; Lv, Y; Lv, Z; Ni, C; Weng, X; Xia, W; Xin, Y; Xu, Q; Yang, L; Yuan, H; Zhang, W, 2018) |
| "The occurrence of metastasis was ascertained monthly by a qualified oncologist, and confirmed, if necessary, by biopsy." | 5.36 | Acetyl salicylic acid (aspirin) improves synthesis of maspin and lowers incidence of metastasis in breast cancer patients [corrected]. ( Bhattacharyya, M; Chakraborty, S; Ghosh, R; Girish, GV; Sinha, AK, 2010) |
| "Vanadium is a trace element widely distributed in the environment." | 5.35 | Vanadium(IV) complexes inhibit adhesion, migration and colony formation of UMR106 osteosarcoma cells. ( Cortizo, AM; Etcheverry, SB; Molinuevo, MS, 2008) |
| "Aspirin given in a lower dose (20 mg/kg) did not show significant difference from the vehicle group." | 5.27 | Reductive effect of aspirin treatment on primary tumor growth and metastasis of implanted fibrosarcoma in rats. ( Hulsman, LO; Kort, WJ; van Schalkwijk, WP; Weijma, IM; Westbroek, DL; Zondervan, PE, 1986) |
| "Distant metastases are the principal cause of death from cancer." | 5.26 | Aspirin for reducing cancer metastases? ( Choppala, JD; Henschke, UK; Luande, GJ, 1977) |
| "23 (60%) of 38 human breast carcinomas had significant in-vitro osteolytic activity." | 5.26 | Breast-cancer osteolysis, bone metastases, and anti-osteolytic effect of aspirin. ( Dowsett, M; Easty, DM; Easty, GC; Neville, AM; Powles, TJ, 1976) |
| " To test whether disruption of platelet function with clopidogrel and aspirin would decrease the number of circulating tumor cells (CTCs) in patients with metastatic breast cancer, a randomized phase II study was performed." | 5.17 | A randomized phase II trial investigating the effect of platelet function inhibition on circulating tumor cells in patients with metastatic breast cancer. ( Eby, CS; Johnson, F; Lammers, PE; Naughton, MJ; Pluard, TJ; Roop, RP; Schneider, JG; Van Poznak, C; Weilbaecher, KN, 2013) |
| " We conducted a prospective randomized trial of alpha-interferon given with or without indomethacin to patients with malignant melanoma to determine what effect, if any, indomethacin might have on the toxic, immunomodulatory, and therapeutic properties of interferon in this disease." | 5.06 | Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma. ( Clark, JW; Crum, E; Hawkins, MJ; Jones, MJ; Longo, DL; McKnight, JE; Miller, RL; Smith, JW; Steis, RG; Urba, WJ, 1989) |
| " This review examines the clinical pharmacology of low-dose aspirin as a basis for discussing the mechanisms underlying the contribution of platelets to neoplastic transformation and progression of cancer via the development of metastases." | 4.98 | Aspirin, platelet inhibition and cancer prevention. ( Patrignani, P; Patrono, C, 2018) |
| " Two reviewers applied pre-determined eligibility criteria (cross-sectional, cohort and controlled studies, and aspirin taken after a diagnosis of cancer), assessed study quality and extracted data on cancer cause-specific deaths, overall mortality and incidence of metastases." | 4.93 | Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies. ( Dolwani, S; Elwood, PC; Galante, J; Kelson, M; Morgan, G; Morris, D; Pickering, JE; Weightman, AL, 2016) |
| " Allocation to aspirin reduced risk of cancer with distant metastasis (all cancers, hazard ratio [HR] 0·64, 95% CI 0·48-0·84, p=0·001; adenocarcinoma, HR 0·54, 95% CI 0·38-0·77, p=0·0007; other solid cancers, HR 0·82, 95% CI 0·53-1·28, p=0·39), due mainly to a reduction in proportion of adenocarcinomas that had metastatic versus local disease (odds ratio 0·52, 95% CI 0·35-0·75, p=0·0006)." | 4.88 | Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. ( Belch, JF; Meade, TW; Mehta, Z; Price, JF; Rothwell, PM; Wilson, M, 2012) |
| "Clinical evidence recently suggests that the regular use of aspirin is associated with a lower risk of breast cancer metastasis, but mechanisms remain unclear." | 4.12 | Aspirin suppresses breast cancer metastasis to lung by targeting anoikis resistance. ( Chen, W; Dong, Z; Li, H; Xu, R; Yan, Y; Zhang, H; Zheng, X, 2022) |
| "Aspirin reduces the incidence of conventional adenomas driven by APC mutation and thus colorectal cancer." | 4.02 | Aspirin reduces the incidence of metastasis in a pre-clinical study of Braf mutant serrated colorectal neoplasia. ( Bond, CE; Fennell, LJ; Kane, AM; Leggett, BA; Liu, C; McKeone, DM; Pollock, PM; Whitehall, VLJ; Young, G, 2021) |
| " Aspirin use post-diagnosis may modify components of the PI3K pathway, including AKT and mTOR, and has been associated with lower risk of breast cancer recurrence and mortality." | 3.96 | Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer. ( Armstrong, K; Bardia, A; Chan, AT; He, W; Iafrate, AJ; Kumar, NP; McCarthy, AM; Moy, B; Regan, S; Welch, M, 2020) |
| "Metformin can induce breast cancer (BC) cell apoptosis and reduce BC local and metastatic growth in preclinical models." | 3.83 | Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. ( Albini, A; Bertolini, F; Calleri, A; Dallaglio, K; Gregato, G; Labanca, V; Mancuso, P; Noonan, DM; Orecchioni, S; Reggiani, F; Rossi, T; Talarico, G, 2016) |
| "Sorafenib is considered to be the first-line therapy for advanced hepatocellular carcinoma (HCC)." | 3.81 | Down-regulation of SDF1-α expression in tumor microenvironment is associated with aspirin-mediated suppression of the pro-metastasis effect of sorafenib in hepatocellular carcinoma. ( Chen, J; Jia, H; Lu, L; Lu, M; Pei, Y; Qin, L; Zhu, W, 2015) |
| "MTT assay, colony formation assay, and apoptosis assay were employed to analyze the effects of aspirin on the osteosarcoma cell viability in vitro." | 3.81 | Aspirin Suppresses the Growth and Metastasis of Osteosarcoma through the NF-κB Pathway. ( Duan, T; Hu, K; Kang, T; Liao, D; Lv, X; Wang, G; Wang, X; Zhang, RH; Zhong, L, 2015) |
| "We previously demonstrated the pro-metastasis effect of sorafenib in hepatocellular carcinoma (HCC), which is mediated by down-regulation of tumor suppressor HTATIP2." | 3.79 | Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma. ( Ao, JY; Chai, ZT; Kong, LQ; Li, JQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Zhang, KZ; Zhang, QB; Zhang, W; Zhang, YY; Zhu, XD, 2013) |
| "Recent evidence suggests that daily aspirin use decreases cancer risk, particularly for colorectal cancer, but evidence for alternate-day use is scant." | 3.79 | Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. ( Buring, JE; Cook, NR; Lee, IM; Moorthy, MV; Zhang, SM, 2013) |
| "From the Swedish Cancer Register, we identified patients diagnosed with colorectal, lung, prostate and breast cancers between 2006 and 2009 and matched them to the Swedish Prescribed Drug Register to obtain information on low-dose aspirin use prior to diagnosis." | 3.79 | Low-dose aspirin use and cancer characteristics: a population-based cohort study. ( Czene, K; Jonsson, F; Lundholm, C; Pawitan, Y; Smedby, KE; Yin, L, 2013) |
| " In this regard, we compared the effects of NONO-aspirin and a novel NONO-naproxen to those exerted by their respective parent NSAIDs on avidities of human melanoma M624 cells." | 3.78 | Effects of nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NONO-NSAIDs) on melanoma cell adhesion. ( Cheng, H; Lee, SH; Mollica, MY; Velázquez-Martínez, CA; Wang, L; Wu, S, 2012) |
| " The effects of warfarin, aspirin and heparin administration on the early arrest patterns of 125IdUrd-labelled TA3 carcinoma and Gardner lymphosarcoma cells injected intravenously into tumor-bearing mice were examined." | 3.66 | Initial tumor cell arrest in animals of defined coagulative status. ( Glaves, D; Weiss, L, 1978) |
| "The frequency of metastases of malignant diethylnitrosamine-induced hepatomas and haemangioendotheliomas of the liver of female Sprague-Dawley rats (29%) was not influenced by application of acetyl-salicylic acid or phenprocoumon." | 3.65 | [Studies on the influence of anticoagulants on metastase formation of autochthonic hepatomas in the rat (author's transl)]. ( Schmähl, D, 1975) |
| " We therefore assessed the effect of Indomethacin and aspirin on some parameters of calcium metabolism in patients with breast cancer." | 3.65 | Failure of indomethacin to reduce hypercalcemia in patients with breast cancer. ( Bondy, PK; Coombes, RC; Neville, AM; Powles, TJ, 1976) |
| "Aspirin could reduce the risk of cancer metastasis." | 2.87 | The effect of aspirin on circulating tumor cells in metastatic colorectal and breast cancer patients: a phase II trial study. ( Chen, Y; Hu, X; Lv, Y; Lv, Z; Ni, C; Weng, X; Xia, W; Xin, Y; Xu, Q; Yang, L; Yuan, H; Zhang, W, 2018) |
| "For example, cancer changes platelet behavior by directly inducing tumor-platelet aggregates, triggering platelet granule and extracellular vesicle release, altering platelet phenotype and platelet RNA profiles, and enhancing thrombopoiesis." | 2.58 | Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents. ( Ni, H; Xu, XR; Yousef, GM, 2018) |
| "Cancer metastasis is a dynamic process during which cancer cells separate from a primary tumor, migrate through the vessel wall into the bloodstream, and extravasate at distant sites to form secondary colonies." | 2.58 | Carpe low-dose aspirin: the new anti-cancer face of an old anti-platelet drug. ( McCarty, OJT; Mitrugno, A; Rigg, RA; Shatzel, JJ; Sylman, JL; Tassi Yunga, S; Williams, CD, 2018) |
| "Recent studies in esophagogastric cancer help clarify the role of radiation therapy in surgical management, as well as the role of chemotherapeutic and targeted agents." | 2.53 | An update in the nonendoscopic treatment of gastric cancer. ( Ilson, DH, 2016) |
| "In lay terms "cancers follow bleeding", which seems to be true for antithrombotic agents in general." | 2.52 | Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges. ( Cabrera-Fuentes, HA; Cherepanov, V; Kim, MH; Serebruany, VL, 2015) |
| "Reduction in distant metastasis and improvements in cancer outcomes appear within 5 years of randomization indicating that aspirin affects tumour growth or the development and spread of metastases from existing cancers or both." | 2.50 | Aspirin in gastrointestinal oncology: new data on an old friend. ( Langley, RE; Rothwell, PM, 2014) |
| "Platelets also promoted cancer cell invasion in vitro." | 1.56 | Platelets disrupt vasculogenic mimicry by cancer cells. ( Bonder, CS; Cockshell, MP; Dale, BJ; Ebert, LM; Hyslop, SR; Josefsson, EC; Martini, C; Thompson, EJ; Woods, AE, 2020) |
| "Aspirin (ASP), which has the activity of anti-metastasis and enhancing T cells infiltration in tumors, is encapsulated into the HS-DTX micelle." | 1.51 | In Vivo Environment-Adaptive Nanocomplex with Tumor Cell-Specific Cytotoxicity Enhances T Cells Infiltration and Improves Cancer Therapy. ( Cheng, H; Huang, X; Lang, T; Li, Y; Liu, Y; Wang, G; Yin, Q; Zheng, Z, 2019) |
| "However, postsurgical metastasis poses an immense setback in cancer therapy." | 1.51 | Minimal dosing of leukocyte targeting TRAIL decreases triple-negative breast cancer metastasis following tumor resection. ( Himmel, LE; Jyotsana, N; King, MR; Yu, F; Zhang, Z, 2019) |
| "We found that it may be advisable for prostate cancer patients to take aspirin to improve their survival for both prostate cancer mortality and other mortality outcomes." | 1.51 | Aspirin Use and Lethal Prostate Cancer in the Health Professionals Follow-up Study. ( Allard, CB; Chan, JM; Downer, MK; Giovannucci, E; Kenfield, SA; Mucci, LA; Preston, MA; Stampfer, MJ; Wilson, KM, 2019) |
| " Long-term administration of aspirin leads to reduced distant metastases in murine models and clinical trials, but the COX isoform, downstream prostanoid, and cell compartment responsible for this effect are yet to be determined." | 1.51 | Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2. ( Allen, PD; Armstrong, PC; Cerutti, C; Gil-Bernabé, AM; Gomes, AL; Lucotti, S; Markelc, B; Mitchell, JA; Muschel, RJ; Ridley, AJ; Smart, S; Soyer, M; Warner, TD; Watson, K, 2019) |
| "Of note, patients with breast cancer receiving aspirin had lower circulating IL-8, and their platelets did not increase tumor cell invasion compared with patients not receiving aspirin." | 1.51 | Aspirin inhibits platelets from reprogramming breast tumor cells and promoting metastasis. ( Battinelli, EM; Ceglowski, JR; Chen, WY; El-Husayni, S; Forward, JA; Italiano, JE; Johnson, KE; Kulenthirarajan, R; Machlus, KR; Malloy, MW; Roweth, HG; Tippy, MD, 2019) |
| "The effective targeting of metastasis-related-pathways in cancer holds promise for a new generation of therapeutics." | 1.43 | A novel co-drug of aspirin and ursolic acid interrupts adhesion, invasion and migration of cancer cells to vascular endothelium via regulating EMT and EGFR-mediated signaling pathways: multiple targets for cancer metastasis prevention and treatment. ( Chen, H; Jia, L; Li, T; Liu, Y; Shao, J; Tang, Q; Yang, X; Zheng, G, 2016) |
| " Interestingly, the acute toxic death could not be reached at the maximum administrable dose (5 g/kg)." | 1.42 | Aspirin, lysine, mifepristone and doxycycline combined can effectively and safely prevent and treat cancer metastasis: prevent seeds from gemmating on soil. ( Dong, H; Gao, Y; Jia, L; Li, T; Lu, Y; Ma, J; Shao, J; Tu, X; Wan, L; Wang, J; Xie, F; Xie, J; Xu, B; Xu, H; Zhang, T; Zhu, Y, 2015) |
| "It is unknown why different ovarian cancers have different metastatic phenotypes." | 1.42 | Aspirin and P2Y12 inhibition attenuate platelet-induced ovarian cancer cell invasion. ( Cooke, NM; Kenny, D; O'Leary, J; Sheils, O; Spillane, CD, 2015) |
| "We recently reported reduced prostate cancer (PCa)-specific mortality for β-blocker users among patients receiving androgen-deprivation therapy in a health survey cohort including 655 PCa patients." | 1.40 | Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. ( Fagerland, MW; Fosså, SD; Grytli, HH; Taskén, KA, 2014) |
| "High-risk prostate cancer (PC) has poor outcomes due to therapeutic resistance to conventional treatments, which include prostatectomy, radiation, and hormone therapy." | 1.40 | Aspirin improves outcome in high risk prostate cancer patients treated with radiation therapy. ( Choe, KS; Chun, SG; Hannan, R; Jacobs, CD; Kim, DW; Lotan, Y; Pistenmaa, DA; Roehrborn, CG; Xie, XJ; Yan, J, 2014) |
| "RECK functions as a metastasis suppressor in CCA; upregulation of RECK expression could provide a potential therapy to improve the prognosis of this type of cancer." | 1.37 | Downregulation of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) is associated with enhanced expression of matrix metalloproteinases and cholangiocarcinoma metastases. ( Khuntikeo, N; Loilome, W; Namwat, N; Puapairoj, A; Puetkasichonpasutha, J; Sripa, B; Tassaneeyakul, W; Techasen, A; Wongkham, S; Yongvanit, P, 2011) |
| "The occurrence of metastasis was ascertained monthly by a qualified oncologist, and confirmed, if necessary, by biopsy." | 1.36 | Acetyl salicylic acid (aspirin) improves synthesis of maspin and lowers incidence of metastasis in breast cancer patients [corrected]. ( Bhattacharyya, M; Chakraborty, S; Ghosh, R; Girish, GV; Sinha, AK, 2010) |
| "Vanadium is a trace element widely distributed in the environment." | 1.35 | Vanadium(IV) complexes inhibit adhesion, migration and colony formation of UMR106 osteosarcoma cells. ( Cortizo, AM; Etcheverry, SB; Molinuevo, MS, 2008) |
| "We used human breast cancer (MCF-7) cells that are poorly metastatic but show highly inducible migration to determine bone-derived factors that induce migration of initially non-disseminating breast cancer cells." | 1.32 | Osteoblast-derived oxysterol is a migration-inducing factor for human breast cancer cells. ( Beckedorf, A; Bieberich, E; Silva, J, 2003) |
| "Although no lung metastasis was observed in the rats killed at the end of the period of carcinogen exposure, lung metastasis was found in 100% of animals in all the groups at the end of the experiment." | 1.32 | Suppression of metastasis by nuclear factor kappaB inhibitors in an in vivo lung metastasis model of chemically induced hepatocellular carcinoma. ( Futakuchi, M; Ogawa, K; Shirai, T; Takahashi, S; Tamano, S, 2004) |
| "Aspirin might exert its anti-metastasis effects on ovarian cancer by affecting metastasis-associated gene expression." | 1.32 | Effects of aspirin on metastasis-associated gene expression detected by cDNA microarray. ( Gao, XQ; Han, JX; Huang, HN; Huang, HY; Song, CZ; Yan, S, 2004) |
| " We noted no evidence of a linear dose-response relationship (P for trend = 0." | 1.31 | Aspirin use in relation to risk of prostate cancer. ( Chan, JM; Colditz, GA; Giovannucci, E; Leitzmann, MF; Ma, J; Stampfer, MJ; Willett, WC, 2002) |
| "Treatment with aspirin or sodium salicylate inhibited invasiveness of the LMP1-expressing C33A cells (P < 0." | 1.31 | Aspirin inhibits tumor cell invasiveness induced by Epstein-Barr virus latent membrane protein 1 through suppression of matrix metalloproteinase-9 expression. ( Furukawa, M; Murono, S; Pagano, JS; Sato, H; Takeshita, H; Yoshizaki, T, 2000) |
| "Pulmonary metastases with CT26 cells could be inhibited by induction of thrombocytopenia, and reconstituted by infusion of either murine or human platelets." | 1.27 | Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. ( Ambrogio, C; Coller, BS; Karpatkin, S; Pearlstein, E, 1988) |
| "Aspirin given in a lower dose (20 mg/kg) did not show significant difference from the vehicle group." | 1.27 | Reductive effect of aspirin treatment on primary tumor growth and metastasis of implanted fibrosarcoma in rats. ( Hulsman, LO; Kort, WJ; van Schalkwijk, WP; Weijma, IM; Westbroek, DL; Zondervan, PE, 1986) |
| "Both the B16 melanoma and the MMTV carcinoma parental cell lines, which can be classed as intermediate metastatic, aggregated platelets well." | 1.27 | Tumour-cell-induced platelet aggregation: studies with cloned metastatic and non-metastatic variants. ( Crawford, N; Lampugnani, MG, 1987) |
| "An increase of extrapulmonary metastases was used as a measure of increased redistribution of tumor cells from lungs to other organs." | 1.26 | Influence of aspirin and/or anabolic steroid (nandrolone decanoate) on experimental metastasis formation. ( Boeryd, B; Kanclerz, A; Zbytniewski, Z, 1981) |
| "23 (60%) of 38 human breast carcinomas had significant in-vitro osteolytic activity." | 1.26 | Breast-cancer osteolysis, bone metastases, and anti-osteolytic effect of aspirin. ( Dowsett, M; Easty, DM; Easty, GC; Neville, AM; Powles, TJ, 1976) |
| "Distant metastases are the principal cause of death from cancer." | 1.26 | Aspirin for reducing cancer metastases? ( Choppala, JD; Henschke, UK; Luande, GJ, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 36 (37.11) | 18.7374 |
| 1990's | 2 (2.06) | 18.2507 |
| 2000's | 9 (9.28) | 29.6817 |
| 2010's | 45 (46.39) | 24.3611 |
| 2020's | 5 (5.15) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Q | 1 |
| Zhai, Y | 1 |
| Luo, W | 1 |
| Zhu, Z | 1 |
| Zhang, X | 1 |
| Xie, S | 1 |
| Hong, C | 1 |
| Wang, Y | 1 |
| Su, Y | 1 |
| Zhao, J | 1 |
| Wang, C | 1 |
| Wang, YS | 1 |
| Huang, NK | 1 |
| Lin, YC | 1 |
| Chang, WC | 1 |
| Huang, WC | 1 |
| Xu, R | 1 |
| Yan, Y | 1 |
| Zheng, X | 1 |
| Zhang, H | 1 |
| Chen, W | 1 |
| Li, H | 1 |
| Dong, Z | 1 |
| Liu, Y | 2 |
| Lang, T | 1 |
| Zheng, Z | 1 |
| Cheng, H | 2 |
| Huang, X | 1 |
| Wang, G | 2 |
| Yin, Q | 1 |
| Li, Y | 1 |
| Martini, C | 1 |
| Thompson, EJ | 1 |
| Hyslop, SR | 1 |
| Cockshell, MP | 1 |
| Dale, BJ | 1 |
| Ebert, LM | 1 |
| Woods, AE | 1 |
| Josefsson, EC | 1 |
| Bonder, CS | 1 |
| McCarthy, AM | 1 |
| Kumar, NP | 1 |
| He, W | 1 |
| Regan, S | 1 |
| Welch, M | 1 |
| Moy, B | 1 |
| Iafrate, AJ | 1 |
| Chan, AT | 1 |
| Bardia, A | 1 |
| Armstrong, K | 1 |
| Kane, AM | 1 |
| Liu, C | 1 |
| Fennell, LJ | 1 |
| McKeone, DM | 1 |
| Bond, CE | 1 |
| Pollock, PM | 1 |
| Young, G | 1 |
| Leggett, BA | 1 |
| Whitehall, VLJ | 1 |
| Callier, V | 1 |
| Contursi, A | 1 |
| Sacco, A | 2 |
| Grande, R | 2 |
| Dovizio, M | 2 |
| Patrignani, P | 3 |
| Chen, WY | 2 |
| Holmes, MD | 1 |
| Yang, L | 1 |
| Lv, Z | 1 |
| Xia, W | 1 |
| Zhang, W | 2 |
| Xin, Y | 1 |
| Yuan, H | 1 |
| Chen, Y | 1 |
| Hu, X | 1 |
| Lv, Y | 1 |
| Xu, Q | 1 |
| Weng, X | 1 |
| Ni, C | 1 |
| Mitrugno, A | 1 |
| Sylman, JL | 1 |
| Rigg, RA | 1 |
| Tassi Yunga, S | 1 |
| Shatzel, JJ | 1 |
| Williams, CD | 1 |
| McCarty, OJT | 1 |
| Xu, XR | 1 |
| Yousef, GM | 1 |
| Ni, H | 1 |
| Patrono, C | 2 |
| Li, C | 1 |
| Lin, J | 1 |
| Wu, P | 1 |
| Zhao, R | 1 |
| Zou, J | 1 |
| Zhou, M | 1 |
| Jia, L | 3 |
| Shao, J | 3 |
| Kim, K | 1 |
| Heo, YK | 1 |
| Chun, S | 1 |
| Kim, CH | 1 |
| Bian, Y | 1 |
| Bae, ON | 1 |
| Lee, MY | 1 |
| Lim, KM | 1 |
| Chung, JH | 1 |
| Johnson, KE | 1 |
| Ceglowski, JR | 1 |
| Roweth, HG | 1 |
| Forward, JA | 1 |
| Tippy, MD | 1 |
| El-Husayni, S | 1 |
| Kulenthirarajan, R | 1 |
| Malloy, MW | 1 |
| Machlus, KR | 1 |
| Italiano, JE | 1 |
| Battinelli, EM | 1 |
| Gilligan, MM | 1 |
| Gartung, A | 1 |
| Sulciner, ML | 1 |
| Norris, PC | 1 |
| Sukhatme, VP | 1 |
| Bielenberg, DR | 1 |
| Huang, S | 1 |
| Kieran, MW | 1 |
| Serhan, CN | 1 |
| Panigrahy, D | 1 |
| Lucotti, S | 1 |
| Cerutti, C | 1 |
| Soyer, M | 1 |
| Gil-Bernabé, AM | 1 |
| Gomes, AL | 1 |
| Allen, PD | 1 |
| Smart, S | 1 |
| Markelc, B | 1 |
| Watson, K | 1 |
| Armstrong, PC | 1 |
| Mitchell, JA | 1 |
| Warner, TD | 1 |
| Ridley, AJ | 1 |
| Muschel, RJ | 1 |
| Downer, MK | 1 |
| Allard, CB | 1 |
| Preston, MA | 1 |
| Wilson, KM | 1 |
| Kenfield, SA | 1 |
| Chan, JM | 2 |
| Mucci, LA | 1 |
| Giovannucci, E | 2 |
| Stampfer, MJ | 2 |
| Jyotsana, N | 1 |
| Zhang, Z | 1 |
| Himmel, LE | 1 |
| Yu, F | 1 |
| King, MR | 1 |
| Lu, L | 2 |
| Sun, HC | 1 |
| Chai, ZT | 1 |
| Zhu, XD | 1 |
| Kong, LQ | 1 |
| Wang, WQ | 1 |
| Zhang, KZ | 1 |
| Zhang, YY | 1 |
| Zhang, QB | 1 |
| Ao, JY | 1 |
| Li, JQ | 1 |
| Wang, L | 2 |
| Wu, WZ | 1 |
| Tang, ZY | 1 |
| Cook, NR | 1 |
| Lee, IM | 1 |
| Zhang, SM | 1 |
| Moorthy, MV | 1 |
| Buring, JE | 1 |
| Jonsson, F | 1 |
| Yin, L | 1 |
| Lundholm, C | 1 |
| Smedby, KE | 1 |
| Czene, K | 1 |
| Pawitan, Y | 1 |
| Roop, RP | 1 |
| Naughton, MJ | 1 |
| Van Poznak, C | 1 |
| Schneider, JG | 1 |
| Lammers, PE | 1 |
| Pluard, TJ | 1 |
| Johnson, F | 1 |
| Eby, CS | 1 |
| Weilbaecher, KN | 1 |
| Jacobs, CD | 1 |
| Chun, SG | 1 |
| Yan, J | 2 |
| Xie, XJ | 2 |
| Pistenmaa, DA | 1 |
| Hannan, R | 1 |
| Lotan, Y | 1 |
| Roehrborn, CG | 1 |
| Choe, KS | 1 |
| Kim, DW | 2 |
| Langley, RE | 1 |
| Rothwell, PM | 3 |
| Pathak, RK | 1 |
| Dhar, S | 1 |
| Franco, AT | 1 |
| Corken, A | 1 |
| Ware, J | 1 |
| Liao, D | 1 |
| Zhong, L | 1 |
| Duan, T | 1 |
| Zhang, RH | 1 |
| Wang, X | 1 |
| Hu, K | 1 |
| Lv, X | 1 |
| Kang, T | 1 |
| Cooke, NM | 1 |
| Spillane, CD | 1 |
| Sheils, O | 1 |
| O'Leary, J | 1 |
| Kenny, D | 1 |
| Wan, L | 1 |
| Dong, H | 1 |
| Xu, H | 1 |
| Ma, J | 2 |
| Zhu, Y | 1 |
| Lu, Y | 1 |
| Wang, J | 1 |
| Zhang, T | 1 |
| Li, T | 2 |
| Xie, J | 1 |
| Xu, B | 1 |
| Xie, F | 1 |
| Gao, Y | 1 |
| Tu, X | 1 |
| Serebruany, VL | 1 |
| Cherepanov, V | 1 |
| Cabrera-Fuentes, HA | 1 |
| Kim, MH | 1 |
| Lu, M | 1 |
| Pei, Y | 1 |
| Chen, J | 1 |
| Qin, L | 1 |
| Zhu, W | 1 |
| Jia, H | 1 |
| Talarico, G | 1 |
| Orecchioni, S | 1 |
| Dallaglio, K | 1 |
| Reggiani, F | 1 |
| Mancuso, P | 1 |
| Calleri, A | 1 |
| Gregato, G | 1 |
| Labanca, V | 1 |
| Rossi, T | 1 |
| Noonan, DM | 1 |
| Albini, A | 1 |
| Bertolini, F | 1 |
| Guillem-Llobat, P | 1 |
| Bruno, A | 1 |
| Ricciotti, E | 1 |
| Cufino, V | 1 |
| Alberti, S | 1 |
| Arena, V | 1 |
| Cirillo, M | 1 |
| FitzGerald, GA | 1 |
| Steinhilber, D | 1 |
| Sgambato, A | 1 |
| Elwood, PC | 1 |
| Morgan, G | 1 |
| Pickering, JE | 1 |
| Galante, J | 1 |
| Weightman, AL | 1 |
| Morris, D | 1 |
| Kelson, M | 1 |
| Dolwani, S | 1 |
| Ilson, DH | 1 |
| Tang, Q | 1 |
| Yang, X | 1 |
| Zheng, G | 1 |
| Chen, H | 1 |
| Shiao, J | 1 |
| Thomas, KM | 1 |
| Rahimi, AS | 1 |
| Rao, R | 1 |
| DaSilva, M | 1 |
| Spangler, A | 1 |
| Leitch, M | 1 |
| Wooldridge, R | 1 |
| Rivers, A | 1 |
| Farr, D | 1 |
| Haley, B | 1 |
| Chen, G | 1 |
| Maddison, P | 1 |
| Green, DL | 1 |
| Karpatkin, S | 2 |
| Ararat, E | 1 |
| Sahin, I | 1 |
| Altundag, K | 1 |
| Bhattacharyya, M | 1 |
| Girish, GV | 1 |
| Ghosh, R | 1 |
| Chakraborty, S | 1 |
| Sinha, AK | 1 |
| Namwat, N | 1 |
| Puetkasichonpasutha, J | 1 |
| Loilome, W | 1 |
| Yongvanit, P | 1 |
| Techasen, A | 1 |
| Puapairoj, A | 1 |
| Sripa, B | 1 |
| Tassaneeyakul, W | 1 |
| Khuntikeo, N | 1 |
| Wongkham, S | 1 |
| Gravitz, L | 1 |
| Algra, AM | 1 |
| Wilson, M | 1 |
| Price, JF | 1 |
| Belch, JF | 1 |
| Meade, TW | 1 |
| Mehta, Z | 1 |
| Mollica, MY | 1 |
| Lee, SH | 2 |
| Velázquez-Martínez, CA | 1 |
| Wu, S | 1 |
| Grytli, HH | 1 |
| Fagerland, MW | 1 |
| Fosså, SD | 1 |
| Taskén, KA | 1 |
| Leitzmann, MF | 1 |
| Colditz, GA | 1 |
| Willett, WC | 1 |
| Silva, J | 1 |
| Beckedorf, A | 1 |
| Bieberich, E | 1 |
| Lloyd, FP | 1 |
| Slivova, V | 1 |
| Valachovicova, T | 1 |
| Sliva, D | 1 |
| Futakuchi, M | 1 |
| Ogawa, K | 1 |
| Tamano, S | 1 |
| Takahashi, S | 1 |
| Shirai, T | 1 |
| Gao, XQ | 1 |
| Han, JX | 1 |
| Huang, HY | 1 |
| Yan, S | 1 |
| Song, CZ | 1 |
| Huang, HN | 1 |
| Molinuevo, MS | 1 |
| Cortizo, AM | 1 |
| Etcheverry, SB | 1 |
| Uluçkan, O | 1 |
| Eagleton, MC | 1 |
| Floyd, DH | 1 |
| Morgan, EA | 1 |
| Hirbe, AC | 1 |
| Kramer, M | 1 |
| Dowland, N | 1 |
| Prior, JL | 1 |
| Piwnica-Worms, D | 1 |
| Jeong, SS | 1 |
| Chen, R | 1 |
| Weilbaecher, K | 1 |
| Mehta, P | 1 |
| Weiss, L | 2 |
| Glaves, D | 2 |
| Grignani, G | 1 |
| Almasio, P | 1 |
| Pacchiarini, L | 1 |
| Ricetti, MM | 1 |
| Serra, L | 1 |
| Gamba, G | 1 |
| Powles, TJ | 6 |
| Dady, PJ | 1 |
| Williams, J | 1 |
| Easty, GC | 5 |
| Coombes, RC | 2 |
| Zbytniewski, Z | 1 |
| Kanclerz, A | 1 |
| Boeryd, B | 1 |
| Klementsen, B | 1 |
| Jørgensen, L | 1 |
| Yamamoto, H | 1 |
| Itoh, F | 1 |
| Fukushima, H | 1 |
| Hinoda, Y | 1 |
| Imai, K | 1 |
| Murono, S | 1 |
| Yoshizaki, T | 1 |
| Sato, H | 1 |
| Takeshita, H | 1 |
| Furukawa, M | 1 |
| Pagano, JS | 1 |
| Dowsett, M | 2 |
| Easty, DM | 4 |
| Neville, AM | 5 |
| Bennett, A | 1 |
| Charlier, EM | 1 |
| McDonald, AM | 1 |
| Simpson, JS | 1 |
| Stamford, IF | 1 |
| Zebro, T | 1 |
| Abrahamsen, AF | 2 |
| Hilgard, P | 3 |
| Heller, H | 1 |
| Schmidt, CG | 1 |
| Carmel, RJ | 1 |
| Brown, JM | 1 |
| Schmähl, D | 1 |
| Seyberth, HW | 1 |
| Segre, GV | 1 |
| Hamet, P | 1 |
| Sweetman, BJ | 1 |
| Potts, JT | 1 |
| Oates, JA | 1 |
| Gazet, JC | 1 |
| Thornes, RD | 1 |
| Henschke, UK | 1 |
| Luande, GJ | 1 |
| Choppala, JD | 1 |
| Pollard, M | 1 |
| Chang, CF | 1 |
| Luckert, PH | 1 |
| Cattan, A | 1 |
| Pourny, C | 1 |
| Carpentier, Y | 1 |
| Cattan, E | 1 |
| Barouh, M | 1 |
| Bondy, PK | 1 |
| Wald, A | 1 |
| Milligan, FD | 1 |
| Miller, RL | 1 |
| Steis, RG | 1 |
| Clark, JW | 1 |
| Smith, JW | 1 |
| Crum, E | 1 |
| McKnight, JE | 1 |
| Hawkins, MJ | 1 |
| Jones, MJ | 1 |
| Longo, DL | 1 |
| Urba, WJ | 1 |
| Talmadge, JE | 1 |
| Bowersox, O | 1 |
| Tribble, H | 1 |
| Shepard, HM | 1 |
| Liggitt, D | 1 |
| Pearlstein, E | 1 |
| Ambrogio, C | 1 |
| Coller, BS | 1 |
| Kort, WJ | 1 |
| Hulsman, LO | 1 |
| van Schalkwijk, WP | 1 |
| Weijma, IM | 1 |
| Zondervan, PE | 1 |
| Westbroek, DL | 1 |
| Lampugnani, MG | 1 |
| Crawford, N | 1 |
| Kolenich, JJ | 1 |
| Mansour, EG | 1 |
| Flynn, A | 1 |
| Gasic, GJ | 2 |
| Gasic, TB | 2 |
| Murphy, S | 2 |
| Wood, S | 1 |
| LiVolsi, VA | 1 |
| Silverstein, MJ | 1 |
| DeKernion, J | 1 |
| Morton, DL | 1 |
| Tobelem, GM | 1 |
| Israel, L | 1 |
| Caen, JP | 1 |
| Clark, SA | 1 |
| Galanti, N | 1 |
| Johnson, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Breast Cancer Active Surveillance Alternative Option, Can Aspirin Make the Difference?[NCT03491410] | Phase 2/Phase 3 | 60 participants (Anticipated) | Interventional | 2018-06-01 | Not yet recruiting | ||
| [NCT02602938] | Phase 2 | 40 participants (Anticipated) | Interventional | 2015-11-30 | Recruiting | ||
| A Prospective Randomized Control Trial of the Effect of Sorafenib Combined With Aspirin in Preventing the Recurrence in High-risk Patients With Hepatocellular Carcinoma[NCT02748304] | 52 participants (Actual) | Interventional | 2016-04-30 | Terminated (stopped due to The enrollment of this study was slow. With the approval of lenvatinib in HCC,many patients choose the new drug, so subsequent enrollment may be more difficult.) | |||
| Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women[NCT00000479] | Phase 3 | 39,876 participants (Actual) | Interventional | 1992-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00000479)
Timeframe: Average follow-up 10.1 years
| Intervention | participants (Number) | |
|---|---|---|
| Total invasive cancer | Cancer death | |
| Aspirin + Vitamin E | 716 | 152 |
| Aspirin Only | 722 | 132 |
| Both Placebos | 706 | 143 |
| Vitamin E Only | 721 | 156 |
(NCT00000479)
Timeframe: Average follow-up 10.1 years
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Major cardiovascular event | Stroke | Myocardial infarction | Cardiovascular death | |
| Aspirin + Vitamin E | 232 | 108 | 102 | 54 |
| Aspirin Only | 245 | 113 | 96 | 66 |
| Both Placebos | 272 | 133 | 99 | 74 |
| Vitamin E Only | 250 | 133 | 94 | 52 |
18 reviews available for aspirin and Neoplasm Metastasis
| Article | Year |
|---|---|
Platelets as crucial partners for tumor metastasis: from mechanistic aspects to pharmacological targeting.
Topics: Animals; Aspirin; Blood Platelets; Eicosanoids; Epithelial-Mesenchymal Transition; Humans; Lysophosp | 2017 |
Role of Aspirin in Breast Cancer Survival.
Topics: Aspirin; Breast Neoplasms; Female; Humans; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Risk | 2017 |
Carpe low-dose aspirin: the new anti-cancer face of an old anti-platelet drug.
Topics: Animals; Antineoplastic Agents; Aspirin; Humans; Neoplasm Metastasis; Neoplasms; Platelet Activation | 2018 |
Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents.
Topics: Aspirin; Blood Platelets; Cell Communication; Cell Proliferation; Extracellular Vesicles; Neoplasm I | 2018 |
Aspirin, platelet inhibition and cancer prevention.
Topics: Animals; Aspirin; Humans; Neoplasm Metastasis; Neoplasms; Platelet Aggregation Inhibitors | 2018 |
Aspirin in gastrointestinal oncology: new data on an old friend.
Topics: Antineoplastic Agents; Aspirin; Gastrointestinal Neoplasms; Humans; Neoplasm Metastasis; Platelet Ag | 2014 |
Platelets at the interface of thrombosis, inflammation, and cancer.
Topics: Animals; Anticarcinogenic Agents; Aspirin; Blood Platelets; Cell Death; Cell Proliferation; Cell-Der | 2015 |
Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges.
Topics: Adenosine; Animals; Anticarcinogenic Agents; Aspirin; Blood Platelets; Carcinogenicity Tests; Clopid | 2015 |
Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Neoplasm Metastasis; Neoplasms | 2016 |
An update in the nonendoscopic treatment of gastric cancer.
Topics: Anticarcinogenic Agents; Aspirin; Chemotherapy, Adjuvant; Esophagogastric Junction; Gastrectomy; Hum | 2016 |
Effect of cancer on platelets.
Topics: Animals; Aspirin; Blood Platelets; Cell Adhesion; Clinical Trials as Topic; Endothelium, Vascular; H | 2009 |
Aspirin intake may prevent metastasis in patients with triple-negative breast cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Female; Humans; Neoplasm Metasta | 2011 |
Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials.
Topics: Antineoplastic Agents; Aspirin; Case-Control Studies; Cohort Studies; Humans; Incidence; Neoplasm Me | 2012 |
Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials.
Topics: Adenocarcinoma; Antineoplastic Agents; Aspirin; Drug Administration Schedule; Female; Humans; Incide | 2012 |
Potential role of platelets in the pathogenesis of tumor metastasis.
Topics: Animals; Aspirin; Blood Platelets; Capillary Permeability; Cell Transformation, Neoplastic; Endothel | 1984 |
Cancer cell damage at the vascular endothelium.
Topics: Animals; Aspirin; Blood Vessels; Capillaries; Endothelium; Fibrin; Heparin; Lung Neoplasms; Microcir | 1983 |
Anticoagulants in the treatment of cancer.
Topics: Ancrod; Animals; Anticoagulants; Aspirin; Coumarins; Factor XIII; Fibrinolytic Agents; Heparin; Huma | 1976 |
[Hemostasis and cancer].
Topics: Anticoagulants; Antifibrinolytic Agents; Aspirin; Blood Coagulation Factors; Cell Adhesion; Endothel | 1974 |
5 trials available for aspirin and Neoplasm Metastasis
| Article | Year |
|---|---|
The effect of aspirin on circulating tumor cells in metastatic colorectal and breast cancer patients: a phase II trial study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomar | 2018 |
A randomized phase II trial investigating the effect of platelet function inhibition on circulating tumor cells in patients with metastatic breast cancer.
Topics: Aspirin; Blood Platelets; Breast Neoplasms; Case-Control Studies; Clopidogrel; Drug Therapy, Combina | 2013 |
Use of inhibitors of prostaglandin synthesis in patients with breast cancer.
Topics: Acetaminophen; Aspirin; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Double-Blind Met | 1980 |
The role of fiberoptic endoscopy in the diagnosis and management of duodenal neoplasms.
Topics: Adenocarcinoma; Adult; Aged; Aspirin; Cautery; Clinical Trials as Topic; Duodenal Neoplasms; Endosco | 1975 |
Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Indomethacin; Interferon Type I; Kil | 1989 |
74 other studies available for aspirin and Neoplasm Metastasis
| Article | Year |
|---|---|
Synthesis and biological properties of polyamine modified flavonoids as hepatocellular carcinoma inhibitors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Aspirin; Car | 2016 |
Aspirin and Sulindac act via different mechanisms to inhibit store-operated calcium channel: Implications for colorectal cancer metastasis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Caco-2 Cells; Calcium Channel Blockers; Calcium Ch | 2022 |
Aspirin suppresses breast cancer metastasis to lung by targeting anoikis resistance.
Topics: Animals; Anoikis; Aspirin; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Lung; Lung Neoplasms; | 2022 |
In Vivo Environment-Adaptive Nanocomplex with Tumor Cell-Specific Cytotoxicity Enhances T Cells Infiltration and Improves Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Aspirin; CD8-Positive T-Lymphocytes; Cell Death; Cell Line, Tumor; D | 2019 |
Platelets disrupt vasculogenic mimicry by cancer cells.
Topics: Animals; Apoptosis; Aspirin; Blood Platelets; Breast Neoplasms; Cell Line, Tumor; Female; Male; Mela | 2020 |
Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Aspi | 2020 |
Aspirin reduces the incidence of metastasis in a pre-clinical study of Braf mutant serrated colorectal neoplasia.
Topics: Adenoma; Animals; Aspirin; Colorectal Neoplasms; Disease Models, Animal; Female; Incidence; Male; Mi | 2021 |
Aspirin vs. Cancer.
Topics: Antineoplastic Agents; Aspirin; Blood Platelets; Gene Expression; Humans; Neoplasm Metastasis; Neopl | 2017 |
Small Molecule Nanodrug Assembled of Dual-Anticancer Drug Conjugate for Synergetic Cancer Metastasis Therapy.
Topics: Animals; Antineoplastic Agents; Aspirin; Cell Line, Tumor; Drug Carriers; Drug Screening Assays, Ant | 2018 |
Arsenic May Act as a Pro-Metastatic Carcinogen Through Promoting Tumor Cell-Induced Platelet Aggregation.
Topics: Animals; Arsenic; Aspirin; Blood Platelets; Cell Adhesion; Cell Line, Tumor; Melanoma; Metalloprotea | 2019 |
Aspirin inhibits platelets from reprogramming breast tumor cells and promoting metastasis.
Topics: Aspirin; Blood Platelets; Breast Neoplasms; Cell Line, Tumor; Cytokines; Female; Humans; Neoplasm Me | 2019 |
Aspirin-triggered proresolving mediators stimulate resolution in cancer.
Topics: Animals; Antineoplastic Agents; Aspirin; Chemokine CCL2; Chemokines; Cytokines; Disease Models, Anim | 2019 |
Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Cell Line, Tumor; Cycloo | 2019 |
Aspirin Use and Lethal Prostate Cancer in the Health Professionals Follow-up Study.
Topics: Adult; Aged; Aspirin; Disease Progression; Follow-Up Studies; Health Personnel; Humans; Male; Middle | 2019 |
Minimal dosing of leukocyte targeting TRAIL decreases triple-negative breast cancer metastasis following tumor resection.
Topics: Animals; Apoptosis; Aspirin; Cell Line, Tumor; Cell Proliferation; Curcumin; Dioxolanes; E-Selectin; | 2019 |
Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma.
Topics: Acetyltransferases; Animals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferatio | 2013 |
Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial.
Topics: Aged; Aspirin; Breast Neoplasms; Colorectal Neoplasms; Drug Administration Schedule; Female; Follow- | 2013 |
Low-dose aspirin use and cancer characteristics: a population-based cohort study.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Cohort Studies; | 2013 |
Aspirin improves outcome in high risk prostate cancer patients treated with radiation therapy.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Chemoradiotherapy; Clopidogrel; Drug Screening Ass | 2014 |
A Nanoparticle Cocktail: Temporal Release of Predefined Drug Combinations.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Cell Line, Tumor; Cisplatin; Drug | 2015 |
Aspirin Suppresses the Growth and Metastasis of Osteosarcoma through the NF-κB Pathway.
Topics: Animals; Apoptosis; Aspirin; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Ce | 2015 |
Aspirin and P2Y12 inhibition attenuate platelet-induced ovarian cancer cell invasion.
Topics: Adenosine Monophosphate; Aspirin; Blood Platelets; Cell Line, Tumor; Female; Flow Cytometry; Humans; | 2015 |
Aspirin, lysine, mifepristone and doxycycline combined can effectively and safely prevent and treat cancer metastasis: prevent seeds from gemmating on soil.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Doxycycline; Drug Interactions; Fe | 2015 |
Down-regulation of SDF1-α expression in tumor microenvironment is associated with aspirin-mediated suppression of the pro-metastasis effect of sorafenib in hepatocellular carcinoma.
Topics: Animals; Aspirin; Benzylamines; Carcinoma, Hepatocellular; Cell Proliferation; Chemokine CXCL12; Cyc | 2015 |
Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells.
Topics: Adipose Tissue, White; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Asp | 2016 |
Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Cell Communication; Cell | 2016 |
A novel co-drug of aspirin and ursolic acid interrupts adhesion, invasion and migration of cancer cells to vascular endothelium via regulating EMT and EGFR-mediated signaling pathways: multiple targets for cancer metastasis prevention and treatment.
Topics: Animals; Aspirin; Biomarkers; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Disease | 2016 |
Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Breast Neop | 2017 |
[Interpretation of the updates of NCCN 2017 version 1.0 guideline for colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2017 |
Effects of aspirin on small-cell lung cancer mortality and metastatic presentation.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2; Female; Humans; Lung Neopl | 2017 |
Acetyl salicylic acid (aspirin) improves synthesis of maspin and lowers incidence of metastasis in breast cancer patients [corrected].
Topics: Adult; Aged; Aspirin; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm R | 2010 |
Downregulation of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) is associated with enhanced expression of matrix metalloproteinases and cholangiocarcinoma metastases.
Topics: Animals; Aspirin; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinom | 2011 |
Chemoprevention: First line of defence.
Topics: Animals; Aspirin; Celecoxib; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Cyclooxygenase I | 2011 |
Effects of nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NONO-NSAIDs) on melanoma cell adhesion.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Azo Compounds; Cell Adhesion; Cell Line | 2012 |
Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Cohort Studies; Humans; Hydroxymethylglutaryl-CoA Reduct | 2014 |
Aspirin use in relation to risk of prostate cancer.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Dose-Response Relatio | 2002 |
Osteoblast-derived oxysterol is a migration-inducing factor for human breast cancer cells.
Topics: Arachidonic Acid; Aspirin; Breast Neoplasms; Cell Membrane; Cell Movement; Cholesterol; Chromatograp | 2003 |
Aspirin inhibits highly invasive prostate cancer cells.
Topics: Actins; Aspirin; Cell Adhesion; Cell Line, Tumor; Cell Movement; Chloramphenicol O-Acetyltransferase | 2003 |
Suppression of metastasis by nuclear factor kappaB inhibitors in an in vivo lung metastasis model of chemically induced hepatocellular carcinoma.
Topics: Acetylcysteine; Animals; Aspirin; Blotting, Western; Carcinogens; Diethylnitrosamine; E-Selectin; En | 2004 |
Effects of aspirin on metastasis-associated gene expression detected by cDNA microarray.
Topics: Aspirin; Cyclooxygenase Inhibitors; Female; Gene Expression Profiling; Gene Expression Regulation, N | 2004 |
Vanadium(IV) complexes inhibit adhesion, migration and colony formation of UMR106 osteosarcoma cells.
Topics: Animals; Aspirin; Cell Adhesion; Cell Line, Tumor; Cell Movement; Colony-Forming Units Assay; Cyclic | 2008 |
APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apyrase; Aspirin; Bone Neoplasms; Diagnosti | 2008 |
Interactions between neoplastic cells with different metastasizing capacity and platelet function.
Topics: Adenosine Diphosphate; Adult; Animals; Aspirin; Blood Platelets; Cell Line; Cells, Cultured; Culture | 1983 |
Influence of aspirin and/or anabolic steroid (nandrolone decanoate) on experimental metastasis formation.
Topics: Animals; Aspirin; Drug Interactions; Mice; Nandrolone; Neoplasm Metastasis; Platelet Aggregation; Sa | 1981 |
Distribution of adhesion molecules on HeLa cells, platelets and endothelium in an in vitro model mimicking the early phase of metastasis. An immunogold electron microscopic study.
Topics: Aspirin; Blood Platelets; Cell Adhesion; Cell Adhesion Molecules; Endothelium, Vascular; Fibrinogen; | 1997 |
Overexpression of cyclooxygenase-2 protein is less frequent in gastric cancers with microsatellite instability.
Topics: Adaptor Proteins, Signal Transducing; Aspirin; Base Pair Mismatch; Carrier Proteins; Cyclooxygenase | 1999 |
Aspirin inhibits tumor cell invasiveness induced by Epstein-Barr virus latent membrane protein 1 through suppression of matrix metalloproteinase-9 expression.
Topics: Animals; Aspirin; Blotting, Western; Cell Nucleus; Chloramphenicol O-Acetyltransferase; Enzyme Inhib | 2000 |
Breast-cancer osteolysis, bone metastases, and anti-osteolytic effect of aspirin.
Topics: Animals; Aspirin; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Cultur | 1976 |
Prostaglandins and breast cancer.
Topics: Adolescent; Adult; Aged; Aspirin; Bone Neoplasms; Breast Neoplasms; Female; Humans; In Vitro Techniq | 1977 |
Anti-inflammatory drugs and tumour growth.
Topics: Animals; Aspirin; Bone Neoplasms; Carcinogens; Drug Evaluation; Humans; Indomethacin; Neoplasm Metas | 1979 |
Platelet turnover in metastatic cancer and the effect of platelet aggregation inhibitors.
Topics: Aspirin; Cell Survival; Dipyridamole; Humans; Neoplasm Metastasis; Platelet Aggregation | 1976 |
The influence of platelet aggregation inhibitors on metastasis formation in mice (3LL).
Topics: Animals; Aspirin; Bencyclane; Cyproheptadine; Dipyridamole; Female; Lung Neoplasms; Male; Mice; Mice | 1976 |
The effect of cyclophosphamide and other drugs on the incidence of pulmonary metastases in mice.
Topics: Age Factors; Animals; Antineoplastic Agents; Aspirin; Cyclophosphamide; Dactinomycin; Dose-Response | 1977 |
[Studies on the influence of anticoagulants on metastase formation of autochthonic hepatomas in the rat (author's transl)].
Topics: Animals; Anticoagulants; Aspirin; Carcinoma, Hepatocellular; Coumarins; Diethylnitrosamine; Female; | 1975 |
Characterization of the group of patients with the hypercalcemia of cancer who respond to treatment with prostaglandin synthesis inhibitors.
Topics: Aspirin; Calcium; Cyclic AMP; Humans; Hypercalcemia; Hyperparathyroidism; Indomethacin; Neoplasm Met | 1976 |
In vitro osteolysis by human breast tumours.
Topics: Aspirin; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Female; Humans; In Vitro Techni | 1977 |
Initial tumor cell arrest in animals of defined coagulative status.
Topics: Animals; Anticoagulants; Aspirin; Blood Coagulation; Carcinoma; Heparin; Lymphoma, Non-Hodgkin; Mice | 1978 |
Aspirin for reducing cancer metastases?
Topics: Animals; Aspirin; Dogs; Humans; Neoplasm Metastasis | 1977 |
Investigations on prostatic adenocarcinomas in rats.
Topics: Adenocarcinoma; Anesthetics; Animals; Aspirin; Cell Line; Female; Immunotherapy; Indomethacin; Lung | 1977 |
Effect of hemostasis modifiers of the activity of VP 16 213 on Lewis lung carcinoma.
Topics: Animals; Aspirin; Etoposide; Hemostasis; Heparin; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neoplasm | 1977 |
Failure of indomethacin to reduce hypercalcemia in patients with breast cancer.
Topics: Aspirin; Bone Neoplasms; Breast Neoplasms; Calcium; Creatinine; Female; Humans; Hydroxyproline; Hype | 1976 |
Toxicity of tumor necrosis factor is synergistic with gamma-interferon and can be reduced with cyclooxygenase inhibitors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Bone Marrow; Cyclooxygenase Inhibi | 1987 |
Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo.
Topics: Animals; Antibodies, Monoclonal; Aspirin; Blood Platelets; Humans; Immunologic Techniques; Lung Neop | 1988 |
Reductive effect of aspirin treatment on primary tumor growth and metastasis of implanted fibrosarcoma in rats.
Topics: Animals; Aspirin; Epoprostenol; Female; Fibrosarcoma; Neoplasm Metastasis; Neoplasm Transplantation; | 1986 |
Tumour-cell-induced platelet aggregation: studies with cloned metastatic and non-metastatic variants.
Topics: Adenosine Diphosphate; Animals; Aspirin; Cell Line; Creatine Kinase; Heparin; Humans; Mammary Neopla | 1987 |
Haematological effects of aspirin.
Topics: Adenocarcinoma; Animals; Aspirin; Heparin; Lung Neoplasms; Mice; Neoplasm Metastasis; Neoplasms, Exp | 1972 |
Anti-metastatic effect of aspirin.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Aspirin; Fibrosarcoma; Humans; Mice; Neoplasm Metast | 1972 |
Aspirin and tumour metastasis.
Topics: Animals; Aspirin; Blood Platelets; Lung Neoplasms; Neoplasm Metastasis; Neoplasms, Experimental; Rab | 1972 |
Anti-metastatic effect of aspirin.
Topics: Animals; Aspirin; Bone Neoplasms; Bone Resorption; Carcinoma 256, Walker; Indomethacin; Lysosomes; N | 1973 |
Anti-metastatic effect of aspirin.
Topics: Animals; Aspirin; Bone Neoplasms; Bone Resorption; In Vitro Techniques; Indomethacin; Mice; Neoplasm | 1973 |
Malignant melanoma metastatic to the bladder. Regression following intratumor injection of BCG vaccine.
Topics: Aspirin; BCG Vaccine; Biopsy; Cystoscopy; Diphenhydramine; Humans; Immunotherapy; Male; Melanoma; Mi | 1974 |
The effect of acetylsalicylic acid and dipyridamole on platelet economy in metastatic cancer.
Topics: Aspirin; Blood Cell Count; Blood Platelets; Cell Survival; Dipyridamole; Half-Life; Humans; Neoplasm | 1972 |
The inhibition by aspirin and indomethacin of osteolytic tumor deposits and hypercalcaemia in rats with Walker tumour, and its possible application to human breast cancer.
Topics: Animals; Aspirin; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Calciu | 1973 |
Platelet-tumor-cell interactions in mice. The role of platelets in the spread of malignant disease.
Topics: Adenocarcinoma; Animals; Aspirin; Blood Cell Count; Blood Platelets; Carcinoma; Cell Survival; Chrom | 1973 |